HSTO News and Press, Histogen Inc. From 03/16/21

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy. SUNY Downstate Medical Cent...

Intec Pharma Ltd (NTEC) +142% on announcing merger agreement with Decoy Biosystems.Check-Cap Ltd. (CHEK) +113% after receiving FDA IDE approval for pivotal study of C-Scan®.Acer Therapeutics (ACER) +67%.Shaw Communications (SJR) +55% as Rogers to acquire the company in C$2...

Histogen (HSTO) shares jump more than 18% during premarket trading after announcing that the FDA has removed the clinical hold on its early-stage HST-003 trial.The company said that the health regulator confirmed that Histogen had satisfactorily addressed all clinical hold questions...

Trial Initiation Anticipated in Second Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that the U.S. Food and Drug Admini...

Histogen (HSTO): Q4 GAAP EPS of -$0.36.Revenue of $0.48M (-9.4% Y/Y) misses by $0.03M.Shares -7.7% AH.Press Release For further details see: Histogen misses on revenue

Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises Initiation of Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients Anticipated in the First Quarter of 2021 HST 003 Trial Initiation for Cartilage Regeneration in...

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function has appo...

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today a...

Canaccord Genuity analyst John Newman has initiated shares of nanocap stock Histogen Inc. (HSTO) with a buy rating and $5 price target.Histogen's pipeline is geared towards aesthetic and therapeutic markets, focusing on hair growth, dermal fillers, and joint cartilage.Newman notes that phase ...

Severn Bancorp (SVBI +82% on merger agreement with Shore Bancshares.Tanger Factory Outlet Centers (SKT) +21%.Allied Esports Entertainment (AESE) +19%.Bellicum Pharmaceuticals (BLCM +14% on first reported use of CaspaCIDe® Safety Switch.Soligenix (SNGX +14% o...